# US 2025/0144215 A1 · Method for enriching tumor infiltrating lymphocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144215 A1
- Document ID: US20250144215A1
- Status: Published application
- Kind: A1
- Application number: 18/832,664
- Filed: 2023-01-27
- Published: 2025-05-08
- Earliest claimed: 2022-01-28
- Assignees: Abelzeta Inc.
- Applicants: Abelzeta Inc.
- Inventors: Xiaobing LUO; Fei TANG; Michael PATRICK; Thu Le TRINH; Jiaqi HUANG; Xin YAO; Shigui ZHU; Yihong YAO
- Web page: https://patentgrep.com/patent/US20250144215A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- C12N 5/0636: {T lymphocytes}
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/30: tumour cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides for improved methods for expanding tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs in a shorter time period than the traditional methods. TIL cell therapy products can be manufactured which easily meet the target cell dose while maintaining desired T cell phenotype.

## Claims

### Claim 1

A method of expanding tumor-infiltrating lymphocytes (TILs), the method comprising:
(a) culturing a first population of cells in a first cell culture medium to generate a second population of cells, wherein the first population of cells is obtained from a tumor sample from a patient; and
(b) contacting the second population of cells with a polymeric matrix comprising anti-CD3 and anti-CD28 antibodies or fragments thereof in a second cell culture medium, to generate a third population of cells, wherein the second cell culture medium comprises about 100 IU/mL to about 8,000 IU/mL interleukin-2 (IL-2).

### Claim 2 (depends on 1)

The method of claim 1, wherein the first cell culture medium comprises about 2,000 IU/mL to about 8,000 IU/mL IL-2.

### Claim 3 (depends on 1)

The method of claim 1, wherein in step (a) the first population of cells is cultured for about 10 days to about 40 days.

### Claim 4 (depends on 3)

The method of claim 3, wherein in step (a) the first population of cells is cultured for about 10 days to about 14 days.

### Claim 5 (depends on 1)

The method of claim 1, wherein the second cell culture medium comprises about 500 IU/mL to about 4,000 IU/mL IL-2.

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein in step (b) the contacting is for about 3 days to about 17 days.

### Claim 9 (depends on 1)

The method of claim 1, wherein the third population of cells is at least 100-fold greater in number than the second population of cells.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the tumor sample is from a solid tumor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the solid tumor comprises a sarcoma, hepatocellular carcinoma, glioma, head-neck cancer, bone cancer, brain cancer, breast cancer, cancer of the anus, cancer of the anal canal, cancer of the anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, cancer of the gallbladder, cancer of the pleura, cancer of the nose, cancer of the nasal cavity, cancer of the middle ear, cancer of the oral cavity, cancer of the vulva, colon cancer, esophageal cancer, cervical cancer, gastrointestinal cancer, hypopharynx cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, nasopharynx cancer, ovarian cancer, pancreatic cancer, peritoneum cancer, omentum cancer, mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, urinary bladder cancer, or combinations thereof.

### Claim 13

(canceled)

### Claim 14

A cell population enriched for, or expanded from, tumor-infiltrating lymphocytes, comprising one or more of the following:
(i) CD3+ CD8+ T cells at a percentage ranging from about 3% to about 88% of CD3+ cells,
(ii) CD3+ CD4+ T cells at a percentage ranging from about 10% to about 96% of CD3+ cells,
(iii) CD4+ TCM T cells at a percentage ranging from about 50% to about 88% of CD4+ cells,
(iv) CD8+ TCM T cells at a percentage ranging from about 28% to about 82% of CD8+ cells,
(v) CD4+ TEM T cells at a percentage ranging from about 11% to about 49% of CD4+ cells, and
(vi) CD8+ TEM T cells at a percentage ranging from about 11% to about 61% of CD8+ cells, wherein the cell population comprises no less than 70% of live cells, and wherein the cell population is generated from a tumor sample from a patient.

### Claim 15 (depends on 14)

The cell population of claim 14, comprising no less than 80% CD3+ T cells in live cells.

### Claim 16 (depends on 14)

The cell population of claim 14, comprising CD4+CD27+ T cells at a percentage ranging from about 10% to about 51% of CD4+ cells.

### Claim 17 (depends on 14)

The cell population of claim 14, comprising CD8+CD27+ T cells at a percentage ranging from about 12% to about 72% of CD8+ cells.

### Claim 18 (depends on 14)

The cell population of claim 14, comprising CD8+CD28+ T cells at a percentage ranging from about 34% to about 95% of CD8+ cells.

### Claim 19 (depends on 14)

The cell population of claim 14, comprising CD4+CD28+ T cells at a percentage ranging from about 82% to about 100% of CD4+ cells.

### Claim 20 (depends on 14)

The cell population of claim 14, comprising CD4+ 4-1BB+ T cells at a percentage ranging from about 0.2% to about 5.8% of CD4+ cells.

### Claim 21 (depends on 14)

The cell population of claim 14, comprising CD8+ 4-1BB+ T cells at a percentage ranging from about 0.2% to about 11.6% of CD8+ cells.

### Claim 22 (depends on 14)

The cell population of claim 14, comprising CD4+ LAG3+ T cells at a percentage ranging from about 0.2% to about 19.5% of CD4+ cells.

### Claim 23 (depends on 14)

The cell population of claim 14, comprising CD8+ LAG3+ T cells at a percentage ranging from about 6% to about 51.2% of CD8+ cells.

### Claim 24 (depends on 14)

The cell population of claim 14, comprising CD4+ PD1+ T cells at a percentage ranging from about 0.9% to about 31% of CD4+ cells.

### Claim 25 (depends on 14)

The cell population of claim 14, comprising CD8+ PD1+ T cells at a percentage ranging from about 1% to about 18% of CD8+ cells.

### Claim 26 (depends on 14)

The cell population of claim 14, comprising no greater than 10% CD56+ NK cells.

### Claim 27

(canceled)

### Claim 28

A method of expanding a cell population enriched for tumor-infiltrating lymphocytes, the method comprising:
(a) culturing cells obtained from a tumor sample from a patient;
(b) treating the cultured cells to generate a cell population enriched for tumor-infiltrating lymphocytes, the cell population comprising one or more of the following:
(i) CD3+ CD8+ T cells at a percentage ranging from about 3% to about 88% of CD3+ cells,
(ii) CD3+ CD4+ T cells at a percentage ranging from about 10% to about 96% of CD3+ cells,
(iii) CD4+ CD45RA−CD62L+ central memory T cells at a percentage ranging from about 50% to about 88% of CD4+ cells,
(iv) CD8+CD45RA−CD62L+ central memory T cells at a percentage ranging from about 28% to about 82% of CD8+ cells,
(v) CD4+CD45RA−CD62L− effector memory T cells at a percentage ranging from about 11% to about 49% of CD4+ cells, and
(vi) CD8+ T CD45RA−CD62L− effector memory T cells at a percentage ranging from about 11% to about 61% of CD8+ cells.

### Claim at position 28

29-33. (canceled)

### Claim 34 (depends on 14)

A method of treating a patient with cancer, the method comprising administering to the patient the cell population of claim 14.

### Claim 35

(canceled)

### Claim 36 (depends on 34)

The method of claim 34, wherein the cancer is melanoma, cervical cancer, lung cancer, colorectal cancer, breast cancer, or head and neck cancer.

### Claim at position 32

37-38. (canceled)
